Low prevalence of IgG antibodies to SARS‐CoV‐2 in cancer patients with COVID‐19
Open Access
- 11 June 2020
- journal article
- letter
- Published by Wiley in International Journal of Cancer
- Vol. 147 (11), 3267-3269
- https://doi.org/10.1002/ijc.33148
Abstract
No abstract availableFunding Information
- The National Cancer Institute (K07CA222343)
- National Basic Research Program of China (2020YFC0845500)
This publication has 10 references indexed in Scilit:
- Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosisJournal of Medical Virology, 2020
- Connecting clusters of COVID-19: an epidemiological and serological investigationThe Lancet Infectious Diseases, 2020
- Antibody responses to SARS-CoV-2 in patients with COVID-19Nature Medicine, 2020
- Virological assessment of hospitalized patients with COVID-2019Nature, 2020
- Antibodies in Infants Born to Mothers With COVID-19 PneumoniaJAMA, 2020
- Effect of changing case definitions for COVID-19 on the epidemic curve and transmission parameters in mainland China: a modelling studyThe Lancet Public Health, 2020
- Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in ItalyJAMA, 2020
- Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in ChinaJournal of Clinical Medicine, 2020
- Cancer patients in SARS-CoV-2 infection: a nationwide analysis in ChinaThe Lancet Oncology, 2020
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020